Dystrophin Isoform Induction In Vivo by Antisense-mediated Alternative Splicing

被引:20
作者
Fletcher, Sue [1 ]
Adams, Abbie M. [1 ]
Johnsen, Russell D. [1 ]
Greer, Kane [1 ]
Moulton, Hong M. [2 ]
Wilton, Steve D. [1 ]
机构
[1] Univ Western Australia, Ctr Neuromuscular & Neurol Disorders, Perth, WA 6009, Australia
[2] Oregon State Univ, Dept Biomed Sci, Coll Vet Med, Corvallis, OR 97331 USA
基金
英国医学研究理事会; 美国国家卫生研究院;
关键词
DUCHENNE MUSCULAR-DYSTROPHY; CONJUGATED MORPHOLINO OLIGOMERS; ACTIN-BINDING DOMAIN; MDX MOUSE; MUSCLE-CELLS; EXPRESSION; GENE; MODEL; MICE; OLIGONUCLEOTIDES;
D O I
10.1038/mt.2010.45
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Antisense oligomer-induced manipulation of dystrophin pre-mRNA processing can remove exons carrying mutations, or exclude exons flanking frameshifting mutations, and restore dystrophin expression in dystrophinopathy models and in Duchenne muscular dystrophy (DMD) patients. Splice intervention can also be used to manipulate the normal dystrophin pre-mRNA processing and ablate dystrophin expression in wild-type mice, with signs of pathology being induced in selected muscles within 4 weeks of commencing treatment. The disruption of normal dystrophin pre-mRNA processing to alter the reading frame can be very efficient and offers an alternative mechanism to RNA silencing for gene suppression. In addition, it is possible to remove in-frame exon blocks from the DMD gene transcript and induce specific dystrophin isoforms that retain partial functionality, without having to generate transgenic animal models. Specific exon removal to yield in-frame dystrophin transcripts will facilitate mapping of functional protein domains, based upon exon boundaries, and will be particularly relevant where there is either limited, or conflicting information as to the consequences of inframe dystrophin exon deletions on the clinical severity and progression of the dystrophinopathy.
引用
收藏
页码:1218 / 1223
页数:6
相关论文
共 46 条
  • [1] Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy
    Aartsma-Rus, A
    Bremmer-Bout, M
    Janson, AAM
    den Dunnen, JT
    van Ommen, GJB
    van Deutekom, JCT
    [J]. NEUROMUSCULAR DISORDERS, 2002, 12 : S71 - S77
  • [2] Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients
    Aartsma-Rus, A
    Janson, AAM
    Kaman, WE
    Bremmer-Bout, M
    den Dunnen, JT
    Baas, F
    van Ommen, GJB
    van Deutekom, JCT
    [J]. HUMAN MOLECULAR GENETICS, 2003, 12 (08) : 907 - 914
  • [3] Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense
    Aartsma-Rus, A
    Janson, AAM
    Kaman, WE
    Bremmer-Bout, M
    van Ommen, GJB
    den Dunnen, JT
    van Deutekom, JCT
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 2004, 74 (01) : 83 - 92
  • [4] Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy
    Aartsma-Rus, Annemieke
    Janson, Anneke A. M.
    van Ommen, Gert-Jan B.
    van Deutekom, Judith C. T.
    [J]. BMC MEDICAL GENETICS, 2007, 8
  • [5] Exploring the frontiers of therapeutic dxon skipping for Duchenne muscular dystrophy by double targeting within one or multiple dxons
    Aartsma-Rus, Annemieke
    Kaman, Wendy E.
    Weij, Rudie
    den Dunnen, Johan T.
    van Ommen, Gert-Jan. B.
    van Deutekom, Judith C. T.
    [J]. MOLECULAR THERAPY, 2006, 14 (03) : 401 - 407
  • [6] Entries in the Leiden Duchenne muscular dystrophy mutation database: An overview of mutation types and paradoxical cases that confirm the reading-frame rule
    Aartsma-Rus, Annemieke
    Van Deutekom, Judith C. T.
    Fokkema, Ivo F.
    Van Ommen, Gert-Jan B.
    Den Dunnen, Johan T.
    [J]. MUSCLE & NERVE, 2006, 34 (02) : 135 - 144
  • [7] Antisense oligonucleotide induced exon skipping and the dystrophin gene transcript: cocktails and chemistries
    Adams, Abbie M.
    Harding, Penny L.
    Iversen, Patrick L.
    Coleman, Catherine
    Fletcher, Sue
    Wilton, Steve D.
    [J]. BMC MOLECULAR BIOLOGY, 2007, 8
  • [8] Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology
    Alter, J
    Lou, F
    Rabinowitz, A
    Yin, HF
    Rosenfeld, J
    Wilton, SD
    Partridge, TA
    Lu, QL
    [J]. NATURE MEDICINE, 2006, 12 (02) : 175 - 177
  • [9] Neutrally charged phosphorodiamidate morpholino antisense oligomers: Uptake, efficacy and pharmacokinetics
    Arora, V
    Devi, GR
    Iversen, PL
    [J]. CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2004, 5 (05) : 431 - 439
  • [10] Functional capacity of dystrophins carrying deletions in the N-terminal actin-binding domain
    Banks, Glen B.
    Gregorevic, Paul
    Allen, James M.
    Finn, Eric E.
    Chamberlain, Jeffrey S.
    [J]. HUMAN MOLECULAR GENETICS, 2007, 16 (17) : 2105 - 2113